Bayzed Health Group Announces Strategic Cooperation with MicroPort Subsidiaries: Weilian Weitong and Mingyue Medical
Key Points of the Announcement
- Strategic Cooperation Agreements: On May 20, 2026, Bayzed Medical Investment Group Company Limited, a wholly owned subsidiary of Bayzed Health Group Inc, entered into strategic cooperation agreements with Shanghai Weichuang Weilian Weitong Health Management Co., Ltd. (“Weilian Weitong”) and Shanghai Mingyue Medical Technology Co., Ltd. (“Mingyue Medical”), both subsidiaries of MicroPort Scientific Corporation.
- Comprehensive Healthcare Sector Collaboration: The agreements cover comprehensive cooperation across the healthcare sector to jointly enhance the standard of medical services.
-
Key Terms of Cooperation:
- Supply Chain Integration: Weilian Weitong and Mingyue Medical will supply Bayzed Group hospitals with a broad range of high-value medical consumables and integrated solutions from MicroPort Scientific’s portfolio.
- Development of Cardiovascular & Cerebrovascular Disciplines: Joint establishment of regional diagnosis and treatment centers for cardiovascular and cerebrovascular conditions. Collaboration includes equipment, technology, specialist resources, and site facilities.
- Establishment of Surgical Robotics Centers: The partners will set up endoscopic and orthopedic surgical robot centers at Bayzed’s hospitals, creating intelligent platforms for clinical diagnosis and treatment, technical training, scientific research, and academic exchange.
-
Strategic Rationale and Benefits:
- The collaboration leverages complementary strengths, particularly in medical artificial intelligence, information technology, and innovative medical equipment.
- Expected to strengthen Bayzed’s capability in complex disease management and minimally invasive surgery, and support expansion in endocrinology and rehabilitation.
- Facilitates the creation of a closed-loop healthcare pathway from in-hospital treatment to out-of-hospital rehabilitation, supporting Bayzed’s “eight-ring” service framework (prevention, screening, diagnosis, treatment, rehabilitation, management, connectivity, and companionship) and the “Hospital at Home” (H@H) continuous healthcare model.
- For Weilian Weitong and Mingyue Medical, the agreement enables broader commercialization of their high-value consumables and integrated solutions, accelerates the establishment of demonstration sites for advanced surgical robotics, and deepens collaboration in clinical training, research, and innovation.
Points of Note for Shareholders (Potentially Price-Sensitive)
- No Definitive Project Agreements Yet: As of the announcement date, no definitive agreements for specific projects under these strategic cooperations have been entered into. There is a possibility that some or all of the intended collaborations may not materialize.
- Not a Notifiable Transaction: The agreements do not constitute a notifiable transaction under Chapter 14 of the Hong Kong Listing Rules and do not require shareholder approval.
- Potential for Future Disclosures: Should any specific projects or transactions arise from these cooperations that require disclosure under Hong Kong Listing Rules, the company will make further announcements.
- Strategic Foundation: This cooperation lays the groundwork for long-term partnerships, with the potential to significantly expand Bayzed’s service offerings, regional coverage, and brand influence in China’s healthcare sector.
- Share Price Sensitivity: The potential for expanded services, advanced medical technology deployment, and enhanced brand influence could positively impact Bayzed’s market position and may be viewed favorably by investors. However, the lack of definitive project agreements introduces uncertainty.
Additional Details
- Independence: Weilian Weitong, Mingyue Medical, and their ultimate beneficial owners are independent third parties and not connected to Bayzed Health Group or its connected persons.
- Board Statement: The Board believes the cooperation is in the best interests of the company and shareholders, supporting Bayzed’s expansion strategy and brand development.
- Directors: The Board consists of Dr. Chen Haoyang (Chairman and Executive Director), Mr. Zhao Yongkai, Ms. Xu Xu, Mr. Lu Jizhong, Mr. Feng Yu, and independent non-executive directors Mr. Chan Hok Leung, Ms. Liu Shuang, and Dr. Guo Wei.
Investor Caution
Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities, given that specific projects under the strategic cooperation have not been finalized and may not materialize.
Disclaimer
This article is based on a company announcement dated May 20, 2026. It is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions.
百澤醫療集團宣布與微創醫療旗下偉聯偉通及明悅醫療展開戰略合作（廣東話版本）
公告重點
- 戰略合作協議：2026年5月20日，百澤醫療投資集團有限公司（百澤醫療集團全資子公司）與上海偉創偉聯偉通健康管理有限公司（「偉聯偉通」）及上海明悅醫療科技有限公司（「明悅醫療」）簽訂戰略合作協議，兩者均為微創醫療科學公司之子公司。
- 全面醫療合作：協議涵蓋醫療行業全方位合作，共同提升醫療服務水平。
-
合作重點：
- 供應鏈協作：偉聯偉通及明悅醫療將為百澤旗下醫院提供微創醫療高值耗材及綜合解決方案。
- 心腦血管學科發展：共同在百澤醫院建立區域性心腦血管診療中心，涵蓋設備、技術、專家資源及場地合作。
- 外科機器人診療中心：共同設立內窺鏡及骨科手術機器人中心，打造集臨床診療、技術培訓、科研及學術交流於一體的智能平台。
-
戰略意義與預期效益：
- 利用彼此在醫療人工智能、信息技術及創新醫療設備的優勢。
- 強化百澤在複雜疾病管理及微創手術的能力，拓展內分泌及康復領域。
- 助力構建從院內治療到院外康復的閉環醫療路徑，支撐“八環”服務框架及“居家醫院”持續健康服務模式。
- 偉聯偉通及明悅醫療可加快其高值耗材與解決方案的商業化，建立手術機器人標桿示範點，深化臨床培訓、科研及創新合作。
股東需注意的重點（或具價格敏感性）
- 尚未簽訂具體項目協議：截至公告日，尚未簽署任何具體項目協議，部分或全部合作或未能落實。
- 不屬於須通報交易：根據香港上市規則第14章，該協議不需股東審批。
- 未來或需公告：如有落實具體項目並觸發披露要求，公司將按規定再作公告。
- 戰略基礎：本次合作為長遠夥伴關係鋪路，有潛力大幅擴展百澤服務範圍及品牌影響力。
- 股價敏感性：服務擴展、醫療技術應用及品牌提升或利好市場，但具體協議未敲定帶來不確定性。
其他詳情
- 獨立性：偉聯偉通、明悅醫療及其最終實益擁有人均為獨立第三方，與百澤醫療集團無關。
- 董事會聲明：董事會認為合作符合公司和股東整體利益，有助於推動集團擴張及品牌建設。
- 董事會成員：陳浩揚醫生（主席及執董）、趙永凱、徐旭、陸繼忠、馮宇及獨立非執董陳學良、劉爽、郭偉博士。
投資者注意
由於具體項目未確定，投資者及股東應審慎處理本公司證券。
免責聲明
本文根據2026年5月20日公司公告編寫，僅供資訊參考，不構成投資建議。投資者應自行作出盡職調查及諮詢專業意見後作出任何投資決定。
